A molecular switch for repairing central nervous system disorders

A molecular switch for repairing central nervous system disorders

Publication date: Jan 11, 2020

Research by Isobel Scarisbrick, Ph. D., published in the Journal of Neuroscience finds that by genetically switching off a receptor activated by blood proteins, named Protease Activated Receptor 1 (PAR1), the body switches on regeneration of myelin, a fatty substance that coats and protects nerves.

However, too much thrombin triggers the PAR1 receptor found on the surface of cells, and this blocks myelin production.

“Our research identifies PAR1 as a molecular switch of myelin regeneration.

In this study, we demonstrate that blocking the function of the PAR1, also referred to as the thrombin receptor, promotes myelin regeneration in two unique experimental models of demyelinating disease. “

One was an acute model of myelin injury and the other studied chronic demyelination, each modeling unique features of myelin loss present in MS, Alzheimer’s disease and other neurological disorders.

The research not only discovered a new molecular switch that turns on myelin regeneration, but also discovered a new interaction between the PAR1 receptor and a very powerful growth system called brain derived neurotropic factor (BDNF).

Significantly, the researchers found that a current Food and Drug Administration-approved drug that inhibits the PAR1 receptor also showed ability to improve myelin production in cells tested in the laboratory.

Concepts Keywords
Alzheimer Nerve injury
BDNF Oligodendrocyte
Blood Remyelination
Blood Proteins Demyelinating disease
Brain Myelin
Central Nervous System Nervous system
Demyelinating Disease Organ systems
Demyelination Glial cells
Fair Dealing Branches of biology
Fertilizer Acute myelin injury
Huntington Diseases
Inhibitor Disease schizophrenia
Insulator Chronic demyelination
Mayo Clinic MS
Multiple Sclerosis Neurological disorders
Myelin Neuron
Myelin Sheath LINGO1
Nervous System Neuroscience
Neurological
Neurological Disorders
Neurotropic
Oligodendroglia
PAR1
Principal Investigator
Protease
Receptor
Scarisbrick
Schizophrenia
Spinal Cord Injury
Thrombin

Semantics

Type Source Name
disease MESH aids
disease MESH schizophrenia
disease MESH Demyelination
drug DRUGBANK Thrombin
disease MESH development
drug DRUGBANK Tropicamide
disease MESH multiple sclerosis
disease MESH central nervous system disorders
disease MESH neurological disorders

Leave a Comment

Your email address will not be published. Required fields are marked *